Current DoD Policy on Kratom and 7-OH

Operation Supplement Safety states that all kratom, mitragynine, and 7-hydroxymitragynine products are prohibited for service members. A September 2025 DoD memorandum addressed active-duty personnel and Reserve Component members, and the Navy issued a service-wide prohibition in 2026. The policy covers products made or derived from kratom, not merely products labeled with the word “kratom.”

This is a significant change from older internet articles that treated kratom as an unregulated gray area. A product being sold at a store or online does not make it permissible under military policy. Service members should check current OPSS resources before using any supplement marketed for energy, pain, mood, focus, sleep, or opioid withdrawal.

Will Kratom Appear on a Standard Military Drug Screen?

Routine military urinalysis focuses on the DoD-authorized drug panel and the testing pattern directed for the specimen. Kratom alkaloids require different analytical targets from the standard opioid panel. It is therefore inaccurate to say either that every sample is tested for kratom or that kratom can never be detected.

Special testing can be directed, panels can change, and laboratories can develop or use assays for emerging substances. Policy violations can also be investigated through evidence other than a routine urinalysis result. No one should use a generalized testing article to calculate whether prohibited use will be discovered.

Why Kratom and Concentrated 7-OH Products Raise Health Concerns

Kratom contains compounds that can produce stimulant-like and opioid-like effects. FDA warns that kratom has been associated with substance use disorder, seizures, liver toxicity, and other serious adverse events. Concentrated 7-OH products may expose a person to substantially different risks than traditional plant material, and no kratom product is FDA-approved to treat pain, anxiety, opioid withdrawal, or another medical condition.

People who use kratom to manage pain or to avoid opioid withdrawal may still need a medical assessment. Abrupt changes can be uncomfortable, and co-use with opioids, alcohol, benzodiazepines, or other sedating substances may increase risk. A qualified clinician—not a supplement seller or referral website—should assess symptoms and recommend care.

What to Do if a Product Contains Kratom, Mitragynine, or 7-OH

1. Do not assume that “natural,” “botanical,” or “legal” means military-permitted.
2. Review the product and ingredient names through the official OPSS index.
3. If the product was used, obtain advice from the appropriate medical, command, supplement-safety, or legal resource based on the situation.
4. If stopping use produces withdrawal symptoms or cravings, seek a clinical assessment rather than attempting to manage the problem alone.

Testing Questions Versus Treatment Questions

A testing question asks whether a laboratory may identify an alkaloid. A treatment question asks whether use is difficult to control, causing withdrawal, interacting with other substances, or affecting health and duty. The second question deserves attention even when no test has occurred. A military program or licensed clinician can assess the situation and explain available care.